コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 following transplantation did not prevent BK viruria.
2 JCV seronegative patients, 10 (37%) had JCV viruria.
3 BK viremia and after no intervention for JC viruria.
4 les from renal allograft recipients with BKV viruria.
5 ositive cytology compared with those without viruria.
6 re associated with a higher frequency of BKV viruria.
7 g BK viremia (0.161 vs. 0.065, P=0.0378) and viruria (0.303 vs. 0.146, P=0.0067) compared with Group
9 equent in putative rejection with concurrent viruria (48.6%), compared with rejection before (9.1%) o
10 Ninety-five (40%) patients had sustained viruria, 48 (20%) sustained viremia, and 17 (7%) biopsy-
12 Of 666 recipients, 250 (37.5%) developed viruria, 80 (12%) developed viremia and 31 (4.7%) develo
13 ing of urinary Haufen and not BK viremia and viruria accurately mark BK polyomavirus nephropathy.
14 omavirus BK (BKV) infection characterized by viruria alone is considered to be of little clinical sig
16 itis is far less frequent than BK viremia or viruria, analysis of risk factors for BKV nephritis as a
17 had BK viruria alone, 61 had BK viremia with viruria and 25 had significant viremia defined as BKV DN
19 a significant risk factor for posttransplant viruria and viremia (OR, 4.52; CI, 2.33-8.77; P < 0.0001
22 comparing the results of JCV serology to JCV viruria and viremia in 67 patients enrolled in a single-
25 statistics showed fair to good agreement of viruria and viremia with BK polyomavirus nephropathy or
29 l reactivation occurs first in the urine (BK viruria) and is associated with a high risk of transplan
31 ive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assa
32 In young seropositive women, CMV DNAemia and viruria are common, which suggests that naturally acquir
33 e planned follow-up period or development of viruria because the trial was stopped early owing to lac
34 hain reaction or in longitudinal DNAemia and viruria between the women with and without serological e
35 fter platelet engraftment with documented BK viruria [BK-HC]) were compared with matched controls.
36 nflammation and tubulitis in the presence of viruria but negative for BKV stains were designated as p
37 igher in renal allograft recipients with BKV viruria, but 58 (50.4%) of 115 renal biopsy samples test
40 sing decoy cells as a marker of polyomavirus viruria cytology has a sensitivity of 41.9% and negative
41 thology in concomitant renal biopsies and BK viruria (decoy cell shedding and viral load assessments
42 primary outcome was time to occurrence of BK viruria (detected using quantitative real-time polymeras
43 ains derived from patients with asymptomatic viruria did not show complete separation from strains as
47 also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of in
48 settings: (i) patients with asymptomatic BK viruria, (ii) patients with active BKVAN, and (iii) pati
50 assess their impact on JC and BK viremia and viruria in 15 healthy subjects, eight human immunodefici
51 ) viruria is more common than BK virus (BKV) viruria in healthy individuals but in kidney transplants
52 -five recipients (40%) had posttransplant BK viruria including 61 with additional viremia and 22 with
53 at intrarenal viral replication in sustained viruria is frequently associated with putative acute rej
54 immunosuppressed patients with polyomavirus viruria is largely supportive and directed toward minimi
56 he presence of BK viruria made concurrent JC viruria less likely: JC viruria was detected in 22% of n
58 athy led to resolution of viremia, decreased viruria levels, and disappearance of viral inclusions, b
63 polyomavirus reactivation (BK viremia or JC viruria) on antibodies to kidney-specific self-antigens
64 94 developed BKV infection (any degree of BK viruria or viremia) whereas 146 developed no infection.
66 significantly higher incidence rates of BKV viruria, Pneumocystis jiroveci pneumonia, and malignancy
70 lant recipients define levels of viremia and viruria that are actionable for additional testing or in
73 -occurrence was 7.6, 7.9, and 9.7 months for viruria, viremia, and polyomavirus-associated nephropath
75 following kidney transplantation, leading to viruria, viremia, and, ultimately, PVAN, is associated w
78 Compared with no viruria (n=515), sustained viruria was associated with more putative rejection epis
81 a made concurrent JC viruria less likely: JC viruria was detected in 22% of non-BK viruric recipients
88 re Haufen-negative, however, high viremia or viruria were detected in 8% and 41% of control samples,
89 Viral loads in patients with asymptomatic viruria were generally lower but in some cases overlappe
93 of clinical presentations from asymptomatic viruria with pyuria to ureteral ulceration with ureteral
94 episodes (52.1%) occurred concurrently with viruria, with a minority before (7.8%) or after (40.1%)
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。